BioStock: Spago Nanomedical on the autumn newsflow

During the second quarter, Lund-based Spago Nanomedical carried out a rights issue securing financial resources to keep up the pace of the development work with Tumorad, the company's radionuclide treatment for cancer. The company's second project, a new contrast agent for MRI diagnostics, is already in clinical trial. BioStock contacted CEO Mats Hansen for an update on the autumn news flow.

Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2022/08/spago-nanomedical-on-the-autumn-newsflow/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/